TY - JOUR
T1 - Autoantibody profile in eosinophilic granulomatosis and polyangiitis
T2 - Predominance of anti-alpha-enolase antibodies
AU - Laskari, K.
AU - Hellmich, B.
AU - Adamus, G.
AU - Csernok, E.
N1 - Publisher Copyright:
© Copyright CliniCal and ExpErimEntal rhEumatology 2021.
PY - 2021
Y1 - 2021
N2 - Objective. To evaluate the autoantibody profile in eosinophilic granulomatosis and polyangiitis (EGPA) patients. Methods. 33 EGPA patients were tested for anti-neutrophil cytoplasmic antibodies (ANCA), antinuclear antibodies (ANA), rheumatoid factor (RF), anti-alpha-enolase antibodies, and anti-eosinophil peroxidase (EPO) antibodies. Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), hypereosinophilic syndrome (HES), rheumatoid arthritis (RA), primary biliary cirrhosis (PBC) patients and healthy subjects were tested as a control group. Results. Anti-alpha-enolase antibodies were positive in 82% of EGPA patients at high titres. Although a high sensitivity was shown for an anti-alpha-enolase antibody titre above 1/100 (82%), the specificity for EGPA remained low (44%) (AUC=0.653, p=0.008). Anti-alpha-enolase antibodies predominated in males with EGPA (p=0.048) and were associated with skin involvement (p=0.040). Most of the EGPA patients positive for anti-alpha enolase antibodies (20 out of 27) had a negative indirect immunofluorescence test (IFT) for ANCA. ANCA were positive in 8 EGPA patients (24%) with a perinuclear pattern in all but one patient. The ANCA-target antigen was myeloperoxidase (MPO) and/or alpha-enolase. A usually fine-speckled ANA pattern was observed in 42% of the EGPA patients. RF was positive in 1 (6%) of the 18 EGPA patients tested. There was no association between the presence and levels of autoantibodies and EGPA disease activity. None of the patients and controls was positive for anti-EPO antibodies. Conclusion. Alpha-enolase may be a target of autoimmunity in EGPA patients and shows usually negative ANCA IFT results.
AB - Objective. To evaluate the autoantibody profile in eosinophilic granulomatosis and polyangiitis (EGPA) patients. Methods. 33 EGPA patients were tested for anti-neutrophil cytoplasmic antibodies (ANCA), antinuclear antibodies (ANA), rheumatoid factor (RF), anti-alpha-enolase antibodies, and anti-eosinophil peroxidase (EPO) antibodies. Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), hypereosinophilic syndrome (HES), rheumatoid arthritis (RA), primary biliary cirrhosis (PBC) patients and healthy subjects were tested as a control group. Results. Anti-alpha-enolase antibodies were positive in 82% of EGPA patients at high titres. Although a high sensitivity was shown for an anti-alpha-enolase antibody titre above 1/100 (82%), the specificity for EGPA remained low (44%) (AUC=0.653, p=0.008). Anti-alpha-enolase antibodies predominated in males with EGPA (p=0.048) and were associated with skin involvement (p=0.040). Most of the EGPA patients positive for anti-alpha enolase antibodies (20 out of 27) had a negative indirect immunofluorescence test (IFT) for ANCA. ANCA were positive in 8 EGPA patients (24%) with a perinuclear pattern in all but one patient. The ANCA-target antigen was myeloperoxidase (MPO) and/or alpha-enolase. A usually fine-speckled ANA pattern was observed in 42% of the EGPA patients. RF was positive in 1 (6%) of the 18 EGPA patients tested. There was no association between the presence and levels of autoantibodies and EGPA disease activity. None of the patients and controls was positive for anti-EPO antibodies. Conclusion. Alpha-enolase may be a target of autoimmunity in EGPA patients and shows usually negative ANCA IFT results.
KW - Anti-alpha-enolase antibodies
KW - Anti-neutrophil cytoplasmic antibodies (ANCA)
KW - Eosinophilic granulomatosis and polyangiitis (EGPA)
UR - http://www.scopus.com/inward/record.url?scp=85107087014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107087014&partnerID=8YFLogxK
M3 - Article
C2 - 33200729
AN - SCOPUS:85107087014
SN - 0392-856X
VL - 39
SP - S83-S87
JO - Clinical and experimental rheumatology
JF - Clinical and experimental rheumatology
IS - 2
ER -